Substituted isoindoles for the treatment and/or prevention of Aβ- related pathologies
    8.
    发明授权
    Substituted isoindoles for the treatment and/or prevention of Aβ- related pathologies 失效
    取代的异吲哚,用于治疗和/或预防相关病理

    公开(公告)号:US08030500B2

    公开(公告)日:2011-10-04

    申请号:US12618212

    申请日:2009-11-13

    IPC分类号: C07D209/44

    摘要: The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Downs syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

    摘要翻译: 本发明涉及新的式(I)化合物及其药物组合物。 此外,本发明涉及用于治疗和/或预防与疾病相关的疾病如唐氏综合征和淀粉样血管病,例如但不限于脑淀粉样血管病或遗传性脑出血的治疗方法,与 认知障碍,例如但不限于MCI(“轻度认知障碍”),阿尔茨海默病,记忆丧失,与阿尔茨海默病相关的注意力缺陷症状,与诸如阿尔茨海默病或痴呆的疾病相关的神经变性,包括混合血管和退行性来源的痴呆, 老年性痴呆,老年性痴呆和与帕金森病相关的痴呆,进行性核上性麻痹或皮质基底变性。

    Compounds and their use as BACE inhibitors
    10.
    发明申请
    Compounds and their use as BACE inhibitors 审中-公开
    化合物及其作为BACE抑制剂的用途

    公开(公告)号:US20120165346A1

    公开(公告)日:2012-06-28

    申请号:US13331231

    申请日:2011-12-20

    CPC分类号: C07D401/14 C07D403/14

    摘要: The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Down's syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

    摘要翻译: 本发明涉及新的式(I)化合物及其药物组合物。 此外,本发明涉及用于治疗和/或预防与疾病相关的病症如唐氏综合征和淀粉样血管病变的治疗方法,例如但不限于脑淀粉样血管病或遗传性脑出血,与 认知障碍,例如但不限于MCI(“轻度认知障碍”),阿尔茨海默病,记忆丧失,与阿尔茨海默病相关的注意力缺陷症状,与诸如阿尔茨海默氏病或​​痴呆症的疾病相关的神经变性,包括混合血管和退行性来源的痴呆, 老年性痴呆,老年性痴呆和与帕金森病相关的痴呆,进行性核上性麻痹或皮质基底变性。